✓ Translated by DotMD AI Clinical Council Source: NEJM evidence • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40693847 ↗

Phase III Randomized Trial: Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2 (N = 58)

Original Paper Title: “Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 58
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures.
  • Study Design & Sample: Phase III Randomized Trial published in NEJM evidence (N = 58 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in NEJM evidence (2025), this phase iii randomized trial evaluating 58 human participants investigated: Revakinagene taroretcel (NT-501) is an encapsulated cell therapy producing ciliary neurotrophic factor that slowed retinal degeneration in patients with macular telangiectasia type 2 (MacTel) in phase 2 trials. Key clinical takeaway: NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (NEJM evidence, 2025-08-15; N = 58; Rigor 82/100): NT-501 for MacTel resulted in statistically significantly reduced EZA loss compared with sham procedures.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Condition: conjunctival-hemorrhage → Condition: optic-disc-swelling-papilledema →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40693847: Phase III Randomized Trial: Cell-Based Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2 (N = 58)

3 of 3 Free Questions Remaining